Autologous adipose MSC, given intravenously, phase 1 done and phase 2 running
Quick answer
ADSTEM inj. is EHL Bio's cell drug using the patient's own adipose-derived mesenchymal stem cells, given as two intravenous infusions, targeting moderate-to-severe subacute and chronic atopic dermatitis. Phase 1 finished in 2017 and the product was approved into phase 2, run at Chung-Ang University Hospital and five other sites.
Atopic dermatitis arises from genetics such as filaggrin gene mutation combined with environmental triggers and immune dysregulation, damaging the skin barrier and driving chronic inflammation. Standard care is topical steroids, immunosuppressants and newer biologics.
The rationale is immune rebalancing. EHL reports that after infusion, regulatory T cells increase and the Th1/Th2 balance is restored, correlating with symptom improvement.
Regulatory-wise, the company describes ADSTEM as Korea's first phase 2 trial of intravenously administered autologous adipose stem cells — meaning it follows the same drug approval pathway as conventional medicines, not a cosmetic service route.
Thai patients should understand this remains investigational and is not a generally registered medicine, so access depends on trial criteria or specific hospital programmes. Discuss it with your treating dermatologist before planning travel.
There is no evidence of a cure. The trial goal is reducing severity and inflammation; skin care and prescribed medication continue alongside.
The ADSTEM protocol specifies two repeat intravenous doses, spaced per protocol.
Trials define eligible age ranges precisely and young children are usually excluded. Check inclusion criteria directly with the study team.
Biologics block one defined inflammatory pathway and are already approved; stem cells act through broad immunomodulation and remain investigational.
5 points • reviewed 2026-08-28
Reviewed and last updated: 2026-08-28
10 sources • every claim is traceable
https://www.ehlbio.co.kr/company/about/
https://www.ehlbio.co.kr/company/history/
https://www.ehlbio.co.kr/rd/gmp/
https://www.ehlbio.co.kr/rd/institute/
https://www.ehlbio.co.kr/rd/patent/
https://www.ehlbio.co.kr/conditioned/
https://www.ehlbio.co.kr/immune_cell/
https://www.ehlbio.co.kr/cure/index/
https://www.ehlbio.co.kr/company/contact/
https://www.ehlbio.co.kr/cure/atopic/
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Cell drug pipeline